Compare Abeona Therapeutics Inc (ABEO) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.46. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | BIL | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $91.77 |
52-Week Low | $4.17 | $91.27 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BIL trades at $91.43, down slightly by 0.01% over 24 hours, with a bearish technical outlook indicated by moving averages. The ETF maintains a consistent dividend payout of $0.27 per share, with recent distributions in H1-26 and upcoming in H2-26. Market sentiment is influenced by Federal Reserve rate hike speculation, as bond ETF inflows surge amid inflation concerns and stock volatility.
The outlook for BIL is cautious due to potential interest rate hikes in 2026, which could impact short-term Treasury yields. Risks include Fed policy uncertainty and macroeconomic shifts, but the ETF offers stability through regular dividends. Investors should weigh yield opportunities against interest rate sensitivity in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
